Abstract
We report a retrospective case series from two UK photobiology units of 12 patients with concomitant atopic dermatitis (AD) and chronic actinic dermatitis (CAD) treated with dupilumab as a systemic monotherapy. While dupilumab is an effective therapy for moderate-to-severe AD, our results suggest that it may be less effective for the photosensitivity of CAD. In 11 of 12 patients with CAD, dupilumab was associated with improvement in dermatitis, but only half the patients noted improvement in photosensitivity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
